查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596403

性與生殖醫學市場：按藥物類型和分銷管道分類的全球預測 - 2025-2030

Sexual & Reproductive Health Drugs Market by Drugs Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年性與生殖藥物市場價值為316.4億美元，預計2024年將達到358.3億美元，複合年成長率為13.34%，到2030年將達到760.3億美元，預計將達到1000萬美元。

生殖醫學市場包括多種旨在解決生殖健康問題和性健康的藥物。此系列包括避孕藥、荷爾蒙療法、更年期管理藥物、勃起功能障礙治療、性行為感染傳染病治療等。這些藥物的需求源於全球對有效生殖健康解決方案的持續需求，這是由於人口成長、性健康意識增強以及對性健康產品的接受程度提高等因素所造成的。治療應用範圍包括避孕、不孕症治療、性別肯定治療和荷爾蒙異常管理，最終用途包括個人、醫療保健提供者和性健康診所。關鍵的成長要素包括生物技術的進步、醫療保健機會的增加以及社會文化的轉變，接受性健康作為整體福祉的重要組成部分。透過遠端醫療解決方案擴大可及性和開發個人化醫療方法存在機會，重點是解決普通人群未滿足的需求。然而，挑戰仍然存在，包括監管障礙、圍繞某些藥物的社會恥辱以及阻礙吸收的潛在副作用。值得探索的創新領域包括非荷爾蒙避孕藥、長效可逆避孕藥（LARC）以及針對特定荷爾蒙途徑且副作用較少的藥物。此外，對奈米技術等新的輸送機制的研究以及對植物來源或天然衍生配方的探索可能會提供競爭優勢。市場的本質是高度動態和競爭的，需要持續投資於研發，以跟上不斷變化的消費者需求和偏好。尋求發展的公司應專注於策略夥伴關係、社區參與以減少恥辱，以及倡導更公平的法規結構以擴大市場准入。對教育和整體健康方法的重視也將在市場擴張中發揮關鍵作用。

主要市場統計
基準年[2023] 316.4億美元
預測年份 [2024] 358.3億美元
預測年份 [2030] 760.3億美元
複合年成長率（%） 13.34%

市場動態：揭示快速發展的性與生殖醫學市場的關鍵市場洞察

供需的動態交互作用正在改變性與生殖醫學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 越來越多的老年婦女尋求藥物
    • 避孕藥具的需求，以防止意外懷孕
    • 智慧型手機和筆記型電腦的網路普及率和可用性較高
  • 市場限制因素
    • 治療和診斷費用上漲
  • 市場機會
    • 加大藥物研發（R&D）力度
    • 提高婦女對避孕器使用的認知
    • 政府對婦女健康的關注與努力
  • 市場問題
    • 與臨床服務相關的巨大財務成本

波特五力：駕馭生殖醫學市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對性與生殖醫學市場的外部影響

外部宏觀環境因素在塑造生殖醫學市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解性與生殖醫學市場的競爭狀況

生殖藥物市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：性與生殖藥物市場供應商的績效評估

FPNV定位矩陣是評估生殖醫學市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製性與生殖醫學市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，生殖醫學市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 尋求藥物的老年婦女人數增加
      • 避孕器的需求，以防止意外懷孕
      • 網路普及率很高，智慧型手機和筆記型電腦也很普及。
    • 抑制因素
      • 治療和診斷費用高
    • 機會
      • 加強藥品研發（R&D）力度
      • 提高婦女對避孕器使用的認知
      • 政府對婦女健康的關注與舉措
    • 任務
      • 與臨床服務相關的巨額成本
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 性與生殖醫學市場：依藥物類型

  • 介紹
  • 勃起功能障礙治療
  • 性別焦慮藥物
  • 性慾減退症治療
  • 早洩治療

第7章 性與生殖醫學市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章美洲性與生殖醫學市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太性與生殖醫學市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的性與生殖醫學市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Bayer AG
  • Bristol Laboratories Ltd.
  • Church & Dwight Co., Inc.
  • Diamond Products
  • Ferring BV
  • Janssen Pharmaceutical Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Viramal Limited
Product Code: MRR-434CCDA0523A

The Sexual & Reproductive Health Drugs Market was valued at USD 31.64 billion in 2023, expected to reach USD 35.83 billion in 2024, and is projected to grow at a CAGR of 13.34%, to USD 76.03 billion by 2030.

The market for sexual and reproductive health drugs encompasses a broad array of pharmaceuticals designed to address reproductive health issues and sexual wellness. This scope includes contraceptives, hormonal therapy, menopause management drugs, drugs for erectile dysfunction, and treatments for sexually transmitted infections. The necessity of these drugs stems from the persistent global demand for effective reproductive health solutions, driven by factors such as a growing population, rising awareness of sexual health, and increased acceptance of sexual wellness products. Applications stretch across contraception, fertility treatments, gender affirmation therapy, and management of hormonal disorders, with significant end-use by individuals, healthcare providers, and clinics dedicated to sexual health. Key growth influencers include advancements in biotechnology, increasing healthcare access, and sociocultural shifts toward embracing sexual health as a critical component of overall well-being. Opportunities exist in expanding access through telehealth solutions and developing personalized medicine approaches, with a focus on addressing unmet needs in underrepresented populations. However, challenges persist, such as regulatory hurdles, societal stigma surrounding certain drugs, and potential side effects that hinder widespread adoption. Innovation areas ripe for exploration include non-hormonal contraceptives, long-acting reversible contraceptives (LARCs), and drugs targeting specific hormonal pathways with fewer side effects. Additionally, research into new delivery mechanisms, such as nanotechnology, and exploring plant-based or naturally-derived formulations can offer competitive advantages. The nature of the market is highly dynamic and competitive, with continual investment in R&D required to address the evolving needs and preferences of consumers. Companies seeking growth should focus on strategic partnerships, community engagement to reduce stigma, and advocacy for more equitable regulatory frameworks to broaden market reach. Emphasizing education and holistic health approaches will also play a pivotal role in market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 31.64 billion
Estimated Year [2024] USD 35.83 billion
Forecast Year [2030] USD 76.03 billion
CAGR (%) 13.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sexual & Reproductive Health Drugs Market

The Sexual & Reproductive Health Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising population of the elder female demanding medicines
    • Demand for contraceptives to prevent unintended pregnancies
    • High internet penetration and availability of smartphones and laptops
  • Market Restraints
    • High cost of treatment and diagnostics
  • Market Opportunities
    • Increasing efforts into research and development (R&D) of drugs
    • Growing awareness among ladies about the use of contraceptives
    • Government concerns and initiatives towards women's health
  • Market Challenges
    • Enormous financial costs associated with the clinical services

Porter's Five Forces: A Strategic Tool for Navigating the Sexual & Reproductive Health Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sexual & Reproductive Health Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sexual & Reproductive Health Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sexual & Reproductive Health Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sexual & Reproductive Health Drugs Market

A detailed market share analysis in the Sexual & Reproductive Health Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sexual & Reproductive Health Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sexual & Reproductive Health Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sexual & Reproductive Health Drugs Market

A strategic analysis of the Sexual & Reproductive Health Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sexual & Reproductive Health Drugs Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Bristol Laboratories Ltd., Church & Dwight Co., Inc., Diamond Products, Ferring B.V., Janssen Pharmaceutical Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Reckitt Benckiser Group PLC, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Viramal Limited.

Market Segmentation & Coverage

This research report categorizes the Sexual & Reproductive Health Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drugs Type, market is studied across Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, and Premature Ejaculation Drugs.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising population of the elder female demanding medicines
      • 5.1.1.2. Demand for contraceptives to prevent unintended pregnancies
      • 5.1.1.3. High internet penetration and availability of smartphones and laptops
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing efforts into research and development (R&D) of drugs
      • 5.1.3.2. Growing awareness among ladies about the use of contraceptives
      • 5.1.3.3. Government concerns and initiatives towards women's health
    • 5.1.4. Challenges
      • 5.1.4.1. Enormous financial costs associated with the clinical services
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sexual & Reproductive Health Drugs Market, by Drugs Type

  • 6.1. Introduction
  • 6.2. Erectile Dysfunction Drugs
  • 6.3. Gender Dysphoria Drugs
  • 6.4. Hypoactive Sexual Desire Disorder Drugs
  • 6.5. Premature Ejaculation Drugs

7. Sexual & Reproductive Health Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Online Pharmacy
  • 7.4. Retail Pharmacy

8. Americas Sexual & Reproductive Health Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Sexual & Reproductive Health Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Sexual & Reproductive Health Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bayer AG
  • 2. Bristol Laboratories Ltd.
  • 3. Church & Dwight Co., Inc.
  • 4. Diamond Products
  • 5. Ferring B.V.
  • 6. Janssen Pharmaceutical Inc.
  • 7. Merck & Co., Inc.
  • 8. Novartis AG
  • 9. Pfizer Inc.
  • 10. Reckitt Benckiser Group PLC
  • 11. Teva Pharmaceutical Industries Ltd.
  • 12. Viatris Inc.
  • 13. Viramal Limited

LIST OF FIGURES

  • FIGURE 1. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GENDER DYSPHORIA DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HYPOACTIVE SEXUAL DESIRE DISORDER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PREMATURE EJACULATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2023